RxDoctor Payments Data

Mark Brune, MD

Internal Medicine · Minden, NVNPI 1093723140

Payments from drug & device makers

$5,259in general payments, 2019–2025

Across 334 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$487
  • Pfizer$424
  • Novo Nordisk$330
  • GSK$324
  • Takeda Pharmaceuticals U.S.A., Inc.$260
  • plus $2K from 41 others

What the payments were for

  • Food & beverage$5,22099%
  • Education$381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,259 in reported general payments places this provider in the 85th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$213,062
Medicare patients
494
Services billed
1,872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$159,942
JardianceEmpagliflozin95$126,946
FarxigaDapagliflozin Propanediol29$43,309
TrulicityDulaglutide33$42,637
EliquisApixaban42$41,189
TradjentaLinagliptin30$30,041
RybelsusSemaglutide16$24,340
XareltoRivaroxaban16$22,548
Breo ElliptaFluticasone/Vilanterol29$21,273
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$19,605
Valsartan215$7,752
Repatha SureclickEvolocumab13$6,820
SynthroidLevothyroxine Sodium83$6,585
Rosuvastatin Calcium445$6,430
Losartan Potassium356$3,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$330$184,282116 claims
Boehringer IngelheimJardiance, Tradjenta$161$156,988125 claims
AstraZenecaFarxiga$487$43,30929 claims
Lilly USA, LLCTrulicity$139$42,63733 claims
PfizerEliquis$424$41,18942 claims
GSKBreo Ellipta, Trelegy Ellipta$324$40,87948 claims
AbbVieSynthroid$1,236$6,58583 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Minden

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →